Abstract Details

Title Risk Factors for Peripartum Mood Disorders in Women with MS: A Prospective Study

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (11:45 AM-12:45 PM)

Poster/Presentation
Number 6-014

Objective To deepen our understanding of peripartum mood concerns in women with multiple sclerosis (MS) by assessing the prevalence and temporal pattern of prospectively collected perinatal depression and anxiety as well as contributing risk factors.

Background

Women with neurological conditions may be at higher risk of peripartum depression (PPD) and anxiety, including in MS. The relationship between prospectively collected mood outcomes and postpartum MS clinical course is unknown.

Design/Methods PRISMA is an ongoing prospective registry of women with MS who are pregnant, contemplating pregnancy, or postpartum. For the current analysis, data on the first 53 participants were analyzed. Data include structured depression assessments (MINI/SCID), and serial surveys: Edinburgh Postnatal Depression Scale (EPDS), Hospital Anxiety and Depression Scale (HADS), and sleep (Epworth Sleepiness Scale).

Results Among this cohort (n= 53), 71% were non-Hispanic White; median pre-conception EDSS was 1.5 (IQR 1-2.5). The prevalence of depression (MINI/SCID) at any point in the first 12 months postpartum was 19.51%. The time point with the highest % of EPDS scores of 10 or above was at 1 month postpartum (19%); of these, 78% normalized by 4 months. One month postpartum EPDS scores were correlated with HADS-Anxiety (r=0.68, p<0.05) and HADS-Anxiety scores (r=0.71, p < 0.05). Four month postpartum EPDS scores were correlated with HADS-Depression scores (r=0.68, p<0.05) and HADS-Anxiety scores (r=0.64, p<0.05). Higher EPDS scores were also associated with preconception history of psychiatric disease, but were not correlated with MRI gadolinium positivity or with clinical relapses in the first 3M postpartum.

Conclusions The prevalence of depression in the first 12 months postpartum in this current study was 19.5%, which is higher than the general population and in line with a prior report in MS. The peak incidence at the 1 month postpartum time point suggests the need for early evaluation postpartum and integration of neurological, obstetrical, and psychological care.

Authors/Disclosures
Madeleine Rose (UCSF) PRESENTER	No disclosure on file
Stephanie Hsu	Stephanie Hsu has nothing to disclose.
Ayushi D. Balan (UCSF)	Miss Balan has nothing to disclose.
Annika Anderson	No disclosure on file
Maria K. Houtchens, MD	Dr. Houtchens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche . Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Houtchens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serono. Dr. Houtchens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Cravath. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Beasley . Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Biogen. The institution of Dr. Houtchens has received research support from Genzyme. The institution of Dr. Houtchens has received research support from Biogen. The institution of Dr. Houtchens has received research support from Genentech. The institution of Dr. Houtchens has received research support from Novartis.
Riley Bove, MD, FAAN (University of California, San Francisco)	Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme-Sanofi. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD-Serono. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadenza. The institution of Dr. Bove has received research support from Biogen. The institution of Dr. Bove has received research support from Eli Lilly. The institution of Dr. Bove has received research support from Novartis. The institution of Dr. Bove has received research support from Roche Genentech.

��ɫ��

��ɫ��